CheckMate 142 is a phase II, multicenter, open-label study exploring the efficacy and safety of nivolumab (a PD-1 inhibitor) alone with or without other anti-cancer drugs in treating MSI-H/dMMR mCRC (NCT02060188). This evidence concerns the gene PDCD1 and cancer.